What Makes a Great Banking Partner?

September 9, 2021June 15, 2022 ~ Next Phase Admin ~ Leave a comment

By Rory McCann, Marketing Manager & Conference Producer, LSN

A question not asked enough by early-stage startup founders when looking for banking options is, “Which available resources are specific to the needs of my company and industry?” In a recent conversation with First Republic Bank’s Nishta Rao, we discussed this question, why it isn’t asked enough, and what founders stand to gain when they understand how much more valuable a banking relationship can be when it’s the right fit. We discuss First Republic’s life science toolkit and the resources available to early-stage startups in life science and healthcare.

Listen to our conversation and get to know First Republic Bank at RESI Partnering Week, September 13-15. Sign up today and mark your calendar for the sessions answering your questions about what a powerful banking relationship can do for you.

Tuesday, September 14 | 11 AM EDT

Beyond Banking: Finding the Right Financial Partner for You

Nishta Rao, Managing Director, Life Science, First Republic Bank
Dennis Ford, CEO, Life Science Nation

When your startup firm gains traction, you will inevitably need a bank that can add value and understand your distinct early-stage entrepreneurial needs. There are an array of financial institutions that have programs in the life science market to aid and guide early-stage entrepreneurs to set up the right financial packages. First Republic Bank is a leader in the early-stage life science market with decades of experience and dedicated teams that provide support to scientist entrepreneurs. In this fireside chat, we discuss the programs and services available for startups and how to engage and take advantage of the FRB offerings to help your business grow.

Wednesday, September 15 | 3 PM EDT

How to Evaluate Your Banking Partner Workshop

Nishta Rao, Managing Director, Life Science, First Republic Bank

Life Science companies need more from a bank than just accounts and transactions. The right banking partner brings a mix of excellent service, industry expertise, and the ability to help companies grow. Join Nishta Rao of First Republic Bank to hear what companies should be looking for in a sound banking partner.

RESI Partnering Week Final Agenda

September 9, 2021September 9, 2021 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI Partnering Week, September 13-17, launches next week and featuring a star-studded lineup of panel discussions, live pitch sessions, educational workshops, fireside chats, and partnering. Check out our lineup of pre-recorded content, as well as the schedule of live events across Digital RESI September, RESI AI, and RESI Longevity.

If you haven’t yet signed up to start booking meetings and connecting with investors who are a fit for your product and stage of development, there is still time. Sign up today!

Digital RESI
(September 13-15)

	Monday (9/13)	Tuesday (9/14)	Wednesday (9/15)
9:00 EDT		Company Valuation for Fundraising Workshop
10:00 EDT	Medical Devices Panel	Asia Cross-Border Panel	Corporate VC Panel
11:00 EDT	IPC Session 1: Therapeutics	Beyond Banking: Finding the Right Financial Partner for You	Negotiating Term Sheets Workshop
12:00 EDT	Seed Funds Panel	Tales from the Road Panel	Angels & Family Offices Panel
13:00 EDT	IPC Session 2: Diagnostics	UCSF Innovation Ventures and Entrepreneurship Program Workshop	Financing Scientific Instrumentation as a Startup Company Workshop
13:00 EDT	IPC Session 2: Diagnostics	IPC Session 5: Oncology
14:00 EDT	Big Pharma Panel	Mental & Behavioral Health Panel	IPC Session 8: R&D / Manufacturing Services
15:00 EDT	IPC Session 3: Novel Drug Delivery	Fundraising Bootcamp Workshop	How to Evaluate Your Banking Partner Workshop
16:00 EDT	IPC Session 4: Cardiovascular & Ophthalmic Disorders	IPC Session 6: Medical Devices	IPC Session 9: Therapeutics
17:00 EDT	Why US Biotechs are Coming to Australia… Workshop	IPC Session 7: Therapeutics	IPC Session 10: Medical Devices & Digital Health

RESI AI & RESI Longevity
(September 16-17)

	Thursday (9/16)	Friday (9/17)
10:00 EDT	Healthcare Communications Panel	Accelerated Pharma Development Panel
	Social Isolation & Loneliness Panel	Health & Homecare Panel
11:00 EDT		Commercialization of AI Technologies Workshop
		Medical Accountability & Adherence Panel
12:00 EDT	IPC Session 1: Therapeutics & Devices	IPC Session 2: Digital Health and R&D/Manufacturing
		Designing Innovation in Assisted Living and Aging in Place
13:00 EDT	IPC Session 1: Medical Devices	IPC Session 3: Digital Health
14:00 EDT		Diagnostic Wearables Panel
		Funding and Strategic Directions with the National Institute on Aging Fireside Chat
15:00 EDT	IPC Session 2: Diagnostics & Therapeutics	What Angels, Seed, Venture, Corporate and Family Offices Investors Are Looking For Panel
16:00 EDT	Healthcare Systems and Infrastructure Panel	Precision Medicine Panel
	Creating Better Dementia Care and Promoting Brain Health Panel
	Pre-Recorded Sessions
	Fundraising Bootcamp Workshop
	The Future of Wearables and Older Adults 2021
	Portfolio Spotlight with Mary Furlong & Associates (MFA)
	National Institute on Aging Seed Funding Overview and Portfolio Showcase
	Fundraising Bootcamp Workshop

700+ Investors at RESI Partnering Week

September 9, 2021 ~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, LSN

700+ investors representing VC, Corporate VC, Big Pharma, Angels, Family Offices, and more are meeting virtually across RESI Partnering Week, September 13-17. There is still time to sign up and start booking meetings. The RESI partnering platform is enabled to narrow down searches for investors who are a fit for your product, stage of development, and specific needs unique to your company. Check out the firms attending this week and select the conference you’re interested in to see the firms participating.

RPW Sept. 2021 Confirmed Investors
Confirmed RESI Investors	Confirmed RESI AI Investors	Confirmed RESI Longevity Investors

As of September 8

Hot Longevity Mandates: Japan-Based Pharma

September 7, 2021 ~ Next Phase Admin ~ Leave a comment

The Pharma is a global pharmaceutical company, with headquarters in Japan and USA offices on the East Coast. The Pharma focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the Pharma is actively seeking novel and innovative therapeutic opportunities for in-licensing in CNS and nephrology. In addition, the firm manages an early-stage investment fund (currently $30M) that actively invests in global early-stage opportunities that fit the firm’s areas of interest.

The Pharma is interested in innovative therapeutics that address areas of significant unmet need in CNS and renal diseases. The Pharma is a global leader in CNS, both neurology and psychiatry, opportunistic to all types of indications, both symptomatic and disease-modifying. In nephrology, the firm is particularly interested in novel mechanism addressing both acute and chronic kidney diseases of tubular and glomerular origin, as well as associated inflammatory and fibrotic mechanisms. The firm will consider both clinical and pre-clinical compounds with compelling biological valid proof-of-concept.

The Pharma has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm aims to obtain global commercial rights as a preferential end-goal.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Meet the Innovator’s Pitch Challenge (IPC) Finalists of RESI Partnering Week

September 2, 2021September 3, 2021 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce the Innovator’s Pitch Challenge (IPC) finalists who will be presenting at the upcoming RESI Partnering Week, September 13-17. The IPC continues to see a record number of applicants, establishing itself as a differentiated and effective platform to showcase innovative technologies during a virtual conference age.

Each participating company will have a dedicated landing page with their pitch video and supplementary materials and will participate in a live Q&A session with investors and industry experts providing feedback and questions, which will help companies better prepare for future investor meetings, understand investor perspectives, and enhance their visibility and network. Many past participants have credited the IPC to unexpected follow-up meetings and new connections.

RESI Partnering Week attendees do not want to miss out on these engaging sessions! If you are not registered, it is not too late – you can register here. If you are an active investor interested in getting involved with these sessions, please reach out to research@lifesciencenation.com for more information.

Below are the participating companies – please click on their logos to learn more!

Focused Workshops at RESI Partnering Week

September 2, 2021September 2, 2021 ~ Next Phase Admin ~ Leave a comment

By Gregory Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI Partnering Week (RPW) – September 13-17, 2021 – is much more than an opportunity to meet one-on-one with investors and other key players in the life science space. The conferences also offer quality, live-streaming workshops on an array of hot topics that are particularly relevant to the space, sponsored by our many great partners. The live format allows for interactive Q&A and makes the sessions more dynamic.

Here are some examples of great content you can expect at RPW:

September 13, 5 PM EDT | Digital RESI September

Why US Biotechs are Coming to Australia and How They are Saving in Regulatory Timelines and Considerable Costs
Yvonne Lungershausen, CEO, Avance Clinical

Learn how U.S. biotechs expedite their early phase clinical research program. With no IND required to start your clinical program in Australia, biotechs are able to save up to a year in regulatory timelines and considerable costs.

September 14, 9 AM EDT | Digital RESI September

Company Valuation for Fundraising – Trends and Tools
Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland
Gergely Ivanyi, PharmD, Business Analyst, Venture Valuation

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, it’s important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don’ts when speaking with investors and look at how to value a life science company with no revenues.

September 14, 3PM EDT | Digital RESI September | RESI AI (Pre-Recorded) | RESI Longevity (Pre-Recorded)

Fundraising Bootcamp
Dennis Ford, CEO, Life Science Nation

The Fundraising Boot Camp provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the Changing Investor Landscape, New Categories of Life Science Investors, Debunking the Top 10 Old Myths in Fundraising, Planning & Infrastructure for an Outbound Fundraising Campaign, Building Your Brand Through Consistent Messaging and Key Components of Fundraising Marketing Collateral. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors.

September 15, 11 AM EDT | Digital RESI September

Negotiating Term Sheets: What’s Best for the Company and What’s Best for You?
Instructor to be Announced, McDermott Will & Emery

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

September 15, 1 PM EDT | Digital RESI September

Financing Scientific Instrumentation as a Startup Company
Darren Platt, President, Demetrix
Bryan Leavitt, Managing Partner, Fountainhead Investment Partner
Chad Kobold, Director of Business, Development, Bold View Capital

Over the last several years, a record number of exciting life sciences start-ups have come online. Most of these start-up companies need scientific instrumentation to support their research. But when funds are limited, how can these companies get the instrumentation needed to hit their growth milestones? Workshop will kick off with an overview of the leasing market for start-ups. Expert panel will share their own experiences going through the leasing process and offer valuable lessons learned.

September 17, 11 AM EDT | RESI AI

How to Go to Market: Commercializing AI-Based Health Technologies
Richie Bavasso, MBA, Co-Founder & CEO, nQ Medical Inc.
Carolyn Metnick, JD, Partner, McDermott Will & Emery
Fahad Rahman, MBA, Co-Founder & CEO, Lumi Health
Michael Ryan, JD, Partner, McDermott Will & Emery
Dale Van Demark, JD, Partner, McDermott Will & Emery

This workshop, hosted by our Title Sponsor McDermott Will & Emery, will focus on the various options for and the legal considerations involved with commercializing AI-based healthcare technologies, including regulatory and data strategies. Learn about the range of options, from R&D use to consumer products, from leading members of McDermott’s digital health practice and companies that have blazed the trail.

Sign up to participate at RESI Partnering Week, September 13-17, and learn more about sponsoring workshops at future events!

Artificial Intelligence for Quality Management in Radiology

August 30, 2021 ~ Next Phase Admin ~ Leave a comment

Interview with Aviel Blumenfeld, CEO & Co-Founder of IMedis

By Erika Wu, Business Development Representative, LSN

Aviel Blumenfeld is the CEO & Co-Founder of IMedis, an Israeli-based company that is creating a comprehensive quality management platform for radiology departments using ground-breaking AI technology to improve clinical outcomes, reduce risks of wrong diagnosis, and increase efficiency. IMedis’ solution uses a unique combination of image analysis and text analysis using AI for the detection and surfacing of various failure points throughout the radiology workflow. In addition, IMedis has a strong and cohesive team and is backed by a leading digital health VC. With a growing pipeline of collaborations in pilots, the company is exactly at the deflection point for using digital health for promoting quality-based healthcare. Aviel has worked in the medical devices field for 15 years in various positions including clinical applications specialists, software engineer, algorithm engineer, product manager and VP of R&D. At IMedis, Aviel handles management, strategy, operation, business development and fundraising.

Erika Wu (EW): IMedis pitched at the Innovator’s Pitch Challenge at RESI AI, January 2021 and Digital RESI, March 2021. What are you currently doing to grow IMedis and where is the company right now?

Aviel Blumenfeld (AB): IMedis is focusing on its go-to-market strategy and has already had several first early adopters in the US and UK starting to use Duali-Q for surfacing actionable missed findings in radiology reports. We expect to receive our first FDA clearance for our clinical offering by early 2022 and to start accelerating our commercial activity and growth of the company. Later this year we are planning to have our Series A-round in order to support the early stage of commercialization of the company, expedite development of new solutions and regulatory approvals.

EW: How would you describe AI?

AB: Professionals’ best assistance.

EW: As many were in your shoes at one point, what are some challenges you’ve learned from? Can you provide any advice, and how has your findings impacted your plan moving forward?

AB: In every conversation, you can learn something new, so keep close relationships with your potential customers, users and partners to better understand their needs and motivation. Early stages of a startup company are very fragile. When the pandemic started we were afraid that we would completely lose the attention of our target customers in the US while they were focused on treating COVID patients and significantly reducing their capacity of radiological examinations. We adopted our go-to-market strategy quickly and approached a new geographical market in the UK as we recognized the NHS which strengthened its digital adoption and openness to new technologies. The benefits of our solution are, first of all, for the patients with improved health outcomes, but also for large health systems by promoting early detection of life-threatening diseases — this is why we see a great potential in the UK as well as with large health systems in the US. We are aiming to keep developing our platform to cover more and more potential failure points and to offer the first in kind comprehensive solution for quality assurance in radiology.

Learn more about IMedis and connect with AI investors at Digital RESI AI (September 16-17)!